A Phase 1, Open-label Study to Evaluate the Safety and to Characterize the Pharmacokinetics of a Fixed-Dose Combination Formulation of Ceftibuten-Ledaborbactam Etzadroxil

This is a Phase 1, open-label, two-part, study in approximately 46 healthy adult participants between 18 and 55 years of age (both inclusive) (at least 16 participants in Part 1 and up to 30 participants in Part 2). The study will be conducted at one clinical site in the United States. Participants in Part 1 and Part 2 may be conducted in parallel. The duration of an individual participation will be approximately 46 days for Part 1 and 43 days for Part 2. All participants will be screened within 28 days prior to dosing. They will be admitted to the clinical research unit (CRU) the day prior to dosing and will remain in the CRU until the end of the PK sample collection period. All participants will return to the clinic for follow-up assessments 7 days ± 1 day after the last dose of study intervention.

开始日期2025-01-07

申办/合作机构

Venatorx Pharmaceuticals, Inc.

[+1]

NCT06717269 / Recruiting临床1期

A Phase 1, Open-Label Study in Healthy Volunteers to Evaluate the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, and the Effect of Food and an Acid-reducing Agent on the Pharmacokinetics of NX-5948

This is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study. It is an open-label study evaluating the relative bioavailability of NX-5948 tablets compared to capsules, and the effect of food and an acid-reducing agent on the pharmacokinetics (PK) of NX-5948.

开始日期2024-11-30

申办/合作机构

Nurix Therapeutics, Inc.

NCT06233149 / Not yet recruiting临床1期

A Bioequivalence Study of Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets in Healthy Thai Volunteers Under Fed Condition

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, full replicate crossover design with four-period, two-treatment, and two-sequence under fed condition and at least 7 days washout period between the doses.

开始日期2024-10-01

申办/合作机构

Bio-innova Co., Ltd

100 项与埃索美拉唑镁相关的临床结果

登录后查看更多信息

100 项与埃索美拉唑镁相关的转化医学

登录后查看更多信息

100 项与埃索美拉唑镁相关的专利（医药）

登录后查看更多信息

2,014

项与埃索美拉唑镁相关的文献（医药）

2024-12-01·International Journal of Clinical Pharmacy

Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis

Article

作者: Li, Wanshu ; Lin, Hangjuan ; Jin, Xin ; Xu, Jun ; Fang, Qing ; Yu, Yanan ; Li, Minghui

BACKGROUND:

Proton pump inhibitors (PPIs) are commonly prescribed for treating upper gastrointestinal hemorrhage, eradicating Helicobacter pylori, and stress ulcer prophylaxis, among other digestive system diseases. Recent case reports provided limited evidence of a correlation between PPIs and drug reactions with eosinophilia and systemic symptoms (DRESS). However, there is currently no established association between PPIs and DRESS.

AIM:

This research aimed to identify the associations between PPIs and DRESS using the US Food and Drug Administration Adverse Events Reporting System (FAERS) database.

METHOD:

A retrospective investigation of DRESS associated with six PPIs used FAERS data from Q1 2004 to Q3 2023. Data mining algorithms were used to identify adverse events in the FAERS database that met the following criteria: (1) proportional reporting ratio (PRR) ≥ 2; (2) reporting odds ratio (ROR) > 1; (3) 95% confidence interval (CI) of ROR > 1; (4) Chi-square (χ²) ≥ 4 and case count ≥ 3.

RESULTS:

There were 495 reports of PPI-related DRESS, including pantoprazole (174, 35.2%), omeprazole (103, 20.8%), lansoprazole (103, 20.8%), esomeprazole (101, 20.4%), rabeprazole (8, 1.6%), and dexlansoprazole (6, 1.2%). The results indicated a significant association of three PPIs (pantoprazole, omeprazole, and lansoprazole) with DRESS. The sensitivity analysis demonstrated that only pantoprazole remained significantly associated with DRESS after 10 concomitant drugs had been removed (ROR: 3.00, PRR: 2.99, and information component [IC]: 1.57).

CONCLUSION:

This study identified the signals suggesting a potential association between DRESS and six PPIs. However, more investigation of epidemiological data is required to validate of these conclusions.

2024-12-01·AMERICAN JOURNAL OF VETERINARY RESEARCH

Preliminary evaluation of ionized magnesium levels in dogs on long-term esomeprazole administration

Article

作者: Lee, Seungkeun ; Song, Kunho ; Her, Jiwoong ; Evans, Samantha ; Lee, Jeongmin

Abstract:

OBJECTIVE:

To investigate the level of whole-blood ionized magnesium (iMg) in dogs with long-term use of proton pump inhibitors (PPIs).

METHODS:

The study included 10 client-owned dogs with esomeprazole administration over 6 months and 62 healthy dogs to determine de novo reference interval (RI) of iMg. Dogs that received esomeprazole for 6 months or longer were retrospectively reviewed to determine the incidence of hypo- or hypermagnesemia based on the de novo RI. Additionally, the iMg levels from the study group were compared with those of 20 age-, sex-, and body weight–matched controls from the 62 dogs.

RESULTS:

The median (range) duration of esomeprazole usage was 26 months (6 to 94). The de novo RI for iMg was determined as 0.73 (90% CI, 0.58 to 0.87) to 1.43 mg/dL (90% CI, 1.33 to 1.46). Based on the RI, none of the dogs with long-term esomeprazole developed hypo- or hypermagnesemia. The iMg from the matched control group was 1.17 mg/dL (90% CI, 0.83 to 1.46). The lowest iMg after 6 months of esomeprazole administration (90% CI, 0.96 mg/dL, 0.87 to 1.41) was significantly lower than the control group (P = .031). The iMg measured at the end of long-term esomeprazole treatment was 1.03 mg/dL (90% CI, 0.87 to 1.41) and not significantly different from the control group (P = .179).

CONCLUSIONS:

Ionized hypomagnesemia was not observed after long-term use of esomeprazole in the small number of dogs included in this study. Robust RI needs to be determined in future studies to investigate the incidence of hypomagnesemia in dogs with long-term use of PPIs.

CLINICAL RELEVANCE:

Future studies in a larger number of dogs are warranted to confirm the findings from the present study and to determine whether the long-term use of esomeprazole in dogs is at risk of developing ionized hypomagnesemia.

2024-11-01·CLINICAL THERAPEUTICS

Pharmacokinetics and Pharmacodynamics of a Fixed-Dose Combination of Esomeprazole and Magnesium Hydroxide Compared to the Enteric-Coated Esomeprazole

Article

作者: Bae, Sungyeun ; Kim, Na Young ; Jeon, Inseung ; Kim, Yoonjin ; Yu, Kyung-Sang ; Hong, Sung Hee ; Lee, SeungHwan ; Jang, In-Jin ; Kwon, Jihoon

PURPOSE:

A fixed-dose combination (FDC) of proton pump inhibitors (PPIs) and antacid salts enables rapid acid suppression through the neutralizing effect of the antacid salt and the rapid absorption of PPIs. This study aimed to compare the pharmacokinetics (PKs) and pharmacodynamics (PDs) of a recently formulated FDC of esomeprazole and magnesium hydroxide to the enteric-coated esomeprazole in healthy subjects.

METHODS:

A randomized, open-label, multiple-dose, two-treatment, two-way crossover design was conducted in healthy subjects. Forty-nine subjects were randomized to one of the two treatment sequences and received either the test drug (esomeprazole/magnesium hydroxide 40/350 mg) or reference drug (enteric-coated esomeprazole 40 mg) for 7 days in the first period and the alternative in the second period with a 14-day washout period. Blood samples were collected for up to 24 hours for PK assessment, and 24-hour gastric pH monitoring was conducted for PD assessment both before and after a single administration, as well as at a steady state after seven consecutive days of administration. The PK and PD parameters were compared between the two drugs.

FINDINGS:

After multiple administrations, the median value of time to reach maximum concentration was faster in the test drug than in the reference drug, with a difference of 1.68 hours. The overall systemic exposure of the test drug was similar to that of the reference drug, and the PK parameter fell within the equivalence criteria. The test drug demonstrated a shorter time to reach gastric pH ≥ 4 compared to the reference drug (P = 0.0463). A decrease from baseline in integrated gastric acidity over 24 hours, which represents the degree of inhibition of gastric acid secretion, was equivalent between the two drugs.

IMPLICATIONS:

The fixed-dose combination of esomeprazole and magnesium hydroxide showed rapid absorption and quicker gastric acid suppression than enteric-coated esomeprazole with comparable PK and PD properties.

CLINICALTRIALS:

gov/ct2/show/NCT04324905).

275

项与埃索美拉唑镁相关的新闻（医药）

2024-12-07

·米内网

3家中药企业遭重罚！15个品种被停购，这款中药“无缘”医保，大联盟集采来袭，上海医药亮了

看点 view 本周，政府采购药品新政出炉，1款中药明令禁入医保，68个儿科药可超说明书使用，多名大三甲书记、院长被查；药品市场迎变局，22省联盟集采开标在即，15个品种被暂停采购，85个藏药集采提上日程；企业大新闻，中药贴膏剂龙头进军创新药市场，一专注代谢领域Biotech赴港上市，上海医药1类新药强势登场......医药行业一周大事件，精彩不容错过！米内一周TOP榜米内数据口服糖尿病药王创新高，TOP20大洗牌第十批集采36个品种生变！齐鲁最强主力抗抑郁药TOP20！1类新药暴涨469% 呼吸系统中成药溶液剂TOP20，太极领跑药企动态人福医药18个新品获批，20多款新药在路上倍特药业大丰收！4款注射剂同日获批石药拿下20亿大品种审评药闻石四药入局10亿注射剂狙击超$85亿市场，信达1类新药上市提速 4亿注射剂，康恩贝过评了政府采购药品新政出炉！本国产品报价享20%优惠 12月5日，财政部发布的《关于政府采购领域本国产品标准及实施政策有关事项的通知（征求意见稿）》提出，在政府采购活动中，当本国产品与非本国产品同台竞争时，本国产品的报价将享受20%的价格扣除优惠，即以其报价的80%参与评审。医药制造业属于工业制造品范畴，其细分行业涵盖化学药品原料药制造、化学药品制剂制造、中药饮片加工、中成药生产、生物药品制造等九大领域。随着20%的价格评审优惠政策的实施，内资药企在价格上将获得实质性的竞争优势，尤其是在对价格敏感、成本控制要求高的采购项目中，内资药企有望凭借性价比优势脱颖而出。（财政部）官方严令！这款中药禁止纳入医保 12月4日，国家林业和草原局、国家中医药管理局、国家药监局三部门联合发布《关于切实加强穿山甲保护管理的通知》，其明令指出，严格穿山甲甲片入药管理——继续停止商业性进出口穿山甲及其制品，继续停止穿山甲饮片纳入医保范畴，不得将含穿山甲成份的药物新增纳入医保范畴等。（国家药监局） 85个藏药！七省联盟集采正式启动 12月3日，青海省药械集采网发布《关于开展藏药联合采购的公告》，明确由青海牵头，内蒙古、四川、云南、甘肃、新疆及新疆生产建设兵团等七省（自治区）组成省际采购联盟，拟开展85个藏药联合采购工作。结合藏药临床使用实际，本次联采不要求公立医疗机构提前报量，待采购中选产品公布后，相关公立医疗机构再结合临床诊治需求开展采购。本次联合采购周期原则上为2年，可视情延长，采购周期自中选结果执行之日起计算。（青海省药械集采网） 68款儿科药解锁新用法！超740亿市场利好不断 12月2日，广东省药学会发布《超药品说明书用药目录（儿科2024年版）》，68款儿科药品种（按通用名统计）成功入选，其2023年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端合计销售规模在740亿元以上，不乏静注人免疫球蛋白注射剂、他克莫司胶囊剂、人生长激素注射剂等超50亿元的重磅产品，涉及肾病综合征、重症/难治性幼年皮肌炎、Prader-Willi综合征等超说明书适应症。在用药安全有据可依、有证可循的前提下，超药品说明书儿科药目录（2024版）的发布，或能让更多罕见病患儿临床获益，进一步推动医疗质量的提高。（米内网整理） 12月2日，河南省医保局发布的一则药品联盟采购公告指出，河南牵头开展的联盟集采新增四川省加入。截至目前，本批集采已有山西、内蒙古、辽宁等22个省（市、自治区）参与。据悉，此次联盟集采拟纳入56个品种，分别为国采第四、第五及第七批期满接续的产品，包括艾司奥美拉唑镁肠溶胶囊、布洛芬片、恩格列净片等临床常用药。目前，联盟采购办公室已完成对相关企业申报产品的信息审核，开标结果将指日可待。（河南省医保局）延伸阅读：今年5月，国家医保局在发布的“集采提质扩面”8号文规划中提及，重点指导河南牵头开展国采品种的可替代药品联盟集采，随后10月，河南曾发函邀请兄弟省份医保局参加。此批集采或以综合评审方式开展，相关细则有望在近日公布。价格过高！69个药品被点名了本周，江苏省医保局发布新一批药品预警，共69个药品被点名。其中，1个药品因高于已挂网最高价10倍及以上触发“红三星”预警而被暂停挂网；35个药品价格高于已挂网最高价2倍（含）至10倍不等，触发“红一星”、“红二星”预警，相关企业将被约谈，提醒医疗机构谨慎采购；33个药品价格高于已挂网最高价但不足2倍触发黄色预警。2024年以来，江苏省已先后更新共四十一批药品价格预警，平均每月更新三批以上；从今年整体情况看，因高价触发预警的药品数量在逐渐减少，同时，药品所触发的预警等级也有降低的趋势。（赛柏蓝）瞄准超320亿市场，上海医药1类新药亮眼 12月4日，国家药监局接连发布公告称，上海医药的1类新药戊二酸利那拉生酯胶囊、盛世泰科生物医药1类新药磷酸森格列汀片获批上市。其中，前者为新一代钾离子竞争性酸阻断剂（P-CAB）口服药物，用于严重胃食管返流性疾病；后者属于新一代高选择性DPP-4抑制剂，用于2型糖尿病患者的治疗。在2023年中国三大终端六大市场（统计范围详见本文末），糖尿病用药、治疗与胃酸分泌相关疾病的药物销售规模分别超过610亿元和320亿元。（米内网整理）斥资7.82亿！中药贴膏剂龙头进军创新药市场 12月5日，中药贴膏剂龙头企业之一的羚锐制药发布公告，拟使用自有资金7.82亿元收购银谷制药100%股权。银谷制药成立于2007年，是一家以化学药品（包括创新药和仿制药）研发为核心的创新型制药企业，目前公司在售及在研产品主要集中在骨质疏松、过敏性鼻炎和急慢性呼吸道疾病等领域。（公司公告）延伸阅读：今年四季度以来，医药领域并/收购事件频传，比如：东北制药拟作价1.87亿元收购北京鼎成肽源70%股权，入局CGT赛道；新诺威拟斥资76亿元并购石药百克；科源制药拟通过发行A股股份等方式购买宏济堂股权等。超10亿美元！这款国产ADC成功出海 12月4日，映恩生物宣布，与GSK就一项ADC药物DB-1324达成独家授权协议。根据协议，映恩生物将有望获得3000万美元首付款，及最高9.75亿美元的里程碑金额，协议总金额超过10亿美元；GSK将获得该产品全球（不包括中国大陆、香港地区和澳门地区）的独家授权，以及成功商业化后净销售额支付不同比例的分级特许权使用费，并从中国大陆、香港地区和澳门地区的净销售额中获得特许权使用费。（健识局）延伸阅读：仅在2023年，映恩生物已接连实现了4个ADC药物的License-out交易，授权对象分别是BioNTech和百济神州。今年8月，映恩生物递交了港股上市申请招股书，据其招股书介绍，公司共有12款ADC候选药物，覆盖了HER2、HER3、TROP2等热门靶点，其中HER2 ADC研发进度最快，已进入Ⅲ期临床。最高68%！63个品种主动降价 12月2日，四川省药械招采中心发布《关于公示部分药品降价的通知》。据梳理，此次共有44家企业、63个药品提交了降价申请，价格联动产品及国采中选产品占主导。其中，复方盐酸利多卡因注射液、复方电解质注射液等降幅较大，均超过65%，而明仁福瑞达制药的颈痛颗粒价格下降仅0.02%，为本次降幅最小的产品。（米内网整理）一专注代谢领域Biotech赴港上市 12月3日，港交所官网公示，银诺医药已向港交所递交了IPO申请。银诺医药成立于2014年，致力于研发治疗糖尿病和其他代谢性疾病的创新疗法。公司的长效GLP-1受体激动剂依苏帕格鲁肽α有望即将进入商业化阶段，用于2型糖尿病的单药疗法及与二甲双胍的联合疗法均已在中国递交上市申请在审。此外，银诺医药还有5款处于IND待启动阶段的候选药物，涉及阿尔茨海默病、肥胖、MASH、1型糖尿病等代谢疾病领域。（医药观澜）米内数据：在中国三大终端六大市场，GLP-1受体激动剂2021-2024H1销售额均保持两位数及以上的同比增速，2023年首度突破90亿元，2024上半年已拿下超50亿元。 15个品种被暂停采购 12月3日，上海阳光医药采购网发布《关于暂停部分药品采购资格的通知》，注射用硫酸长春新碱、注射用盐酸阿糖胞苷等15个药品被暂停采购，包括7个因挂网价高的药品，以及8个因企业反馈停产停供的药品。自2024年12月4日起暂停部分药品采购资格。（上海阳光医药采购网）生产销售劣药！3家中药企业遭重罚 12月2日，湖南省药监局发布的三则行政处罚书显示：湖南省弘华中药饮片有限公司因生产销售劣药炒酸枣仁、款冬花、蜜款冬花，被处以没收相关产品违法所得约5.59万元，并处罚金30万元；邵阳神农中药科技发展有限公司因生产销售劣药人参片，被处以没收违法所得约1.67万元，并处罚金10万元；永州市永靛中药饮片股份有限公司因生产销售劣药蜜款冬花、蒲公英，被处以没收相关产品违法所得约1.37万元，并处罚金10万元。上述三家中药企业被合计罚没超58万元。（湖南省药监局）多名三甲医院书记、院长被查 12月2日，湖南省益阳市纪委监委消息称，湖南省益阳市中心医院原党委书记胡丽涉嫌严重违纪违法，目前正接受益阳市纪委监委纪律审查和监察调查。无独有偶，重庆市纪委监委于同日发布消息，重庆市第九人民医院党委书记阳光涉嫌严重违纪违法，目前正接受北碚区纪委监委审查调查。（纪委监委网站）延伸阅读：据不完全统计，今年以来已有超320名医药卫生系统“关键少数”被查，其中超160名为医院书记或院长。仅在上个月（11月），已有至少21名医院书记、院长官宣被查，其中10人来自三甲医院管理层。注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

带量采购一致性评价

2024-12-02

·PRNewswire

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the agreements TEL-AVIV, Israel and RALEIGH, N.C., Dec. 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been awarded approximately $8 million (consisting of $6.5 million plus interest amounting to approximately $1.5 million), plus costs in a summary judgment by the Supreme Court of the State of New York, New York County (the "Court"), in its legal proceedings (Index number: 653200/2022) against Kukbo Co. Ltd. ("Kukbo"), domiciled in South Korea. The case refers to Kukbo's failure to make agreed payments to RedHill, pursuant to a Subscription Agreement (the "SA"), dated October 25, 2021, and a subsequent Exclusive License Agreement (the "ELA" and together with the SA, the "Agreements"), dated March 14, 2022, entered into by the two companies. Dror Ben-Asher, RedHill's CEO: "RedHill thanks the Court for this crystal-clear judgment, affirming the Company's just position from the beginning of the relationship, and in making correct provision for full reparation for the contractual breaches. The Company is also grateful to Haynes and Boone, LLP for their expert counsel and legal representation in this case." Upon entry, Kukbo has a right to seek an appeal of the judgment, which may or may not be granted. RedHill intends to pursue its attorneys' fees and collection of the judgment. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S commercialization and development of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[1]. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), ), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, , targeting multiple indications with a U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 ( upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease. More information about the Company is available at / X.com/RedHillBio. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the legal process going forward including Kukbo's rights to appeal. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the risk that the Court's ruling will not be upheld in any subsequent appeal or that the provisions for reparation for the contractual breaches will not be honored; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, and that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia® and Aemcolo®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law. Category: Corporate Logo: [1] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . SOURCE RedHill Biopharma Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果引进/卖出临床3期

2024-11-24

·信狐药迅

江苏晨泰医药1类新药佐利替尼非小细胞肺癌一线治疗获批上市| 新获批(11.18-11.24）

每周药品注册获批数据，分门别类呈现，一目了然。(11.18-11.24）新药上市申请药品名称企业注册分类受理号盐酸佐利替尼片江苏晨泰医药科技有限公司1CXHS2300020盐酸佐利替尼片江苏晨泰医药科技有限公司1CXHS2300019Belzutifan片MERCK SHARP & DOHME (UK) LIMITED5.1JXHS2400021盐酸氨溴索喷雾剂(II)GMep Medical Technology GmbH5.1JXHS2300104 新药临床申请药品名称企业注册分类受理号D-1553片上海正大天晴医药科技开发有限公司1CXHL2400929IN10018片应世生物科技(上海)有限公司1CXHL2400938IN10018片应世生物科技(上海)有限公司1CXHL2400937注射用PL002浙江普利药业有限公司1CXHL2400936BGB-58067片百济神州(苏州)生物科技有限公司1CXHL2400932BGB-58067片百济神州(苏州)生物科技有限公司1CXHL2400931KPC000154片昆药集团股份有限公司1CXHL2400923KPC000154片昆药集团股份有限公司1CXHL2400922XZP-6924-TS1片轩竹生物科技股份有限公司1CXHL2400915XZP-6924-TS1片轩竹生物科技股份有限公司1CXHL2400914XZP-6924-TS1片轩竹生物科技股份有限公司1CXHL2400913PE-003片原研港生命科学(上海)有限公司1CXHL2400912PE-003片原研港生命科学(上海)有限公司1CXHL2400911HY-072808软膏合肥恩瑞特药业有限公司1CXHL2400904HY-072808软膏合肥恩瑞特药业有限公司1CXHL2400903莫米司特片赣州和美药业股份有限公司1CXHL2400900TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2400878司美格鲁肽注射液华润双鹤药业股份有限公司2.2CXHL2400920司美格鲁肽注射液华润双鹤药业股份有限公司2.2CXHL2400919司美格鲁肽注射液华润双鹤药业股份有限公司2.2CXHL2400918司美格鲁肽注射液华润双鹤药业股份有限公司2.2CXHL2400917司美格鲁肽注射液华润双鹤药业股份有限公司2.2CXHL2400916HQ2216注射液百诚医药(珠海横琴)有限公司2.2CXHL2400875HQ2304胶囊百诚医药(珠海横琴)有限公司2.3CXHL2400902HQ2304胶囊百诚医药(珠海横琴)有限公司2.3CXHL2400901九价人乳头瘤病毒疫苗(大肠埃希菌)厦门万泰沧海生物技术有限公司2.2CXSL2400580注射用Zilovertamab vedotin默沙东研发(中国)有限公司1CXSL2400708注射用ZL-1310再鼎医药(上海)有限公司1CXSL2400609MWN105注射液上海民为生物技术有限公司1CXSL2400608MWN105注射液上海民为生物技术有限公司1CXSL2400607注射用MCLA-129贝达药业股份有限公司1CXSL2400603PJ016注射液重庆派金生物科技有限公司1CXSL2400600注射用SHR-4394江苏恒瑞医药股份有限公司1CXSL2400601LP-003 注射液天辰生物医药(苏州)有限公司1CXSL2400599SHR-1819注射液广东恒瑞医药有限公司1CXSL2400594KYS202003A注射液江苏康缘药业股份有限公司1CXSL2400562 仿制药申请药品名称企业注册分类受理号舒必利注射液海南卓科制药有限公司3CYHS2401731舒必利注射液海南卓科制药有限公司3CYHS2401730乙酰半胱氨酸口服液合肥国药诺和药业有限公司3CYHS2400063乙酰半胱氨酸口服液合肥国药诺和药业有限公司3CYHS2400064帕拉米韦注射液海南海灵化学制药有限公司3CYHS2302122己酮可可碱注射液河北一品生物医药有限公司3CYHS2301677甲硫酸新斯的明注射液山西振东泰盛制药有限公司3CYHS2301639ω-3鱼油中长链脂肪乳/氨基酸(16)/葡萄糖(30)注射液四川科伦药业股份有限公司3CYHS2301614ω-3鱼油中长链脂肪乳/氨基酸(16)/葡萄糖(30)注射液四川科伦药业股份有限公司3CYHS2301613甲硫酸新斯的明注射液合肥亿帆生物制药有限公司3CYHS2301545甲硫酸新斯的明注射液合肥亿帆生物制药有限公司3CYHS2301544甲硫酸新斯的明注射液合肥亿帆生物制药有限公司3CYHS2301543枸橼酸钾缓释片成都硕德药业有限公司3CYHS2301506枸橼酸钾缓释片成都硕德药业有限公司3CYHS2301505硫酸镁注射液重庆药谷制药有限公司3CYHS2301445盐酸纳洛酮注射液西洲医药科技(浙江)有限公司3CYHS2301406盐酸纳洛酮注射液西洲医药科技(浙江)有限公司3CYHS2301405氯化钾颗粒国药集团国瑞药业有限公司3CYHS2301257依帕司他片惠升生物制药股份有限公司3CYHS2301215重酒石酸去甲肾上腺素注射液合肥国药诺和药业有限公司3CYHS2301179重酒石酸去甲肾上腺素注射液合肥国药诺和药业有限公司3CYHS2301178盐酸多巴胺注射液湖南先施制药有限公司3CYHS2301089重酒石酸去甲肾上腺素注射液天方药业有限公司3CYHS2300854米诺地尔外用溶液济南中海医药科技有限公司3CYHS2300679米诺地尔外用溶液济南中海医药科技有限公司3CYHS2300678盐酸氟西汀口服溶液江西施美药业股份有限公司3CYHS2300626注射用尼可地尔瑞阳制药股份有限公司3CYHS2300584注射用尼可地尔瑞阳制药股份有限公司3CYHS2300583氨溴特罗口服溶液亚宝药业四川制药有限公司3CYHS2300572盐酸格拉司琼片杭州和泽坤元药业有限公司3CYHS2300489氨溴特罗口服溶液广东九明制药有限公司3CYHS2300143克林霉素磷酸酯注射液海南通用康力制药有限公司3CYHS2202144国;CYHS2202144克林霉素磷酸酯注射液海南通用康力制药有限公司3CYHS2202143国;CYHS2202143克林霉素磷酸酯注射液海南通用康力制药有限公司3CYHS2202142国;CYHS2202142米诺地尔搽剂安徽省先锋制药有限公司3CYHS2201319国;CYHS2201319米诺地尔搽剂安徽省先锋制药有限公司3CYHS2201318国;CYHS2201318氧(液态)赤峰广钢气体有限公司4CYHS2400361ω-3脂肪酸乙酯90软胶囊温州海鹤药业有限公司4CYHS2400247磷酸奥司他韦胶囊安徽九洲方圆制药有限公司4CYHS2400106酒石酸托特罗定缓释胶囊湖南九典制药股份有限公司4CYHS2302687他克莫司软膏陕西丽彩药业有限公司4CYHS2302517他克莫司软膏陕西丽彩药业有限公司4CYHS2302516沙库巴曲缬沙坦钠片华润双鹤利民药业(济南)有限公司4CYHS2302496沙库巴曲缬沙坦钠片华润双鹤利民药业(济南)有限公司4CYHS2302495甲苯磺酸艾多沙班片辰欣药业股份有限公司4CYHS2302429富马酸喹硫平片成都康弘药业集团股份有限公司4CYHS2302363富马酸喹硫平片成都康弘药业集团股份有限公司4CYHS2302362富马酸喹硫平片成都康弘药业集团股份有限公司4CYHS2302361二甲双胍恩格列净片(V)苏州天马医药集团天吉生物制药有限公司4CYHS2302318二甲双胍恩格列净片(I)苏州天马医药集团天吉生物制药有限公司4CYHS2302317艾司奥美拉唑镁肠溶片石家庄龙泽制药股份有限公司4CYHS2302295阿仑膦酸钠片浙江花园药业有限公司4CYHS2302266甲氨蝶呤注射液浙江华海药业股份有限公司4CYHS2302253利伐沙班片江西同和药业股份有限公司4CYHS2302260利伐沙班片江西同和药业股份有限公司4CYHS2302259利伐沙班片江西同和药业股份有限公司4CYHS2302258孟鲁司特钠咀嚼片山东丹红制药有限公司4CYHS2302243孟鲁司特钠咀嚼片山东丹红制药有限公司4CYHS2302242注射用氯诺昔康东阳祥昇医药科技有限公司4CYHS2302214盐酸鲁拉西酮片江西施美药业股份有限公司4CYHS2302148米库氯铵注射液江苏恩华药业股份有限公司4CYHS2302101米库氯铵注射液江苏恩华药业股份有限公司4CYHS2302100磷酸西格列汀片杨凌步长制药有限公司4CYHS2302073磷酸西格列汀片杨凌步长制药有限公司4CYHS2302072磷酸西格列汀片杨凌步长制药有限公司4CYHS2302071地夸磷索钠滴眼液苏州工业园区天龙制药有限公司4CYHS2302065注射用培美曲塞二钠江苏神曲医药有限公司4CYHS2302050磷酸奥司他韦胶囊福建省宝诺医药研发有限公司4CYHS2302019注射用头孢呋辛钠舒美奇成都生物科技有限公司4CYHS2302002注射用头孢呋辛钠舒美奇成都生物科技有限公司4CYHS2302001白消安注射液中润药业有限公司4CYHS2301987硫酸镁钠钾口服用浓溶液长春澜江医药科技有限公司4CYHS2301925氢溴酸伏硫西汀片北大医药股份有限公司4CYHS2301912氢溴酸伏硫西汀片北大医药股份有限公司4CYHS2301911氢溴酸伏硫西汀片北大医药股份有限公司4CYHS2301910盐酸氮卓斯汀滴眼液苏州工业园区天龙制药有限公司4CYHS2301857苯磺顺阿曲库铵注射液无锡凯夫制药有限公司4CYHS2301843苯磺顺阿曲库铵注射液无锡凯夫制药有限公司4CYHS2301842玻璃酸钠滴眼液成都康弘药业集团股份有限公司4CYHS2301831玻璃酸钠滴眼液华熙生物科技股份有限公司4CYHS2301802乳果糖口服溶液合肥国药诺和药业有限公司4CYHS2301764盐酸屈他维林注射液陕西丽彩药业有限公司4CYHS2301757吸入用复方异丙托溴铵溶液济南景笙科技有限公司4CYHS2301725阿哌沙班片山东鲁抗医药股份有限公司4CYHS2301672布洛芬混悬液哈尔滨葵花药业有限公司4CYHS2301665布洛芬混悬滴剂海南斯达制药有限公司4CYHS2301624硫酸镁钠钾口服用浓溶液浙江高跖医药科技股份有限公司4CYHS2301500富马酸喹硫平缓释片北大医药股份有限公司4CYHS2301282磷酸芦可替尼片成都苑东生物制药股份有限公司4CYHS2301296注射用替考拉宁杭州沐源生物医药科技有限公司4CYHS2301263醋酸曲普瑞林注射液山东新时代药业有限公司4CYHS2301034雷贝拉唑钠肠溶片山东裕欣药业有限公司4CYHS2301028地氯雷他定片北京双鹭药业股份有限公司4CYHS2300996盐酸文拉法辛缓释胶囊浙江九洲生物医药有限公司4CYHS2300959盐酸多奈哌齐片安徽九洲方圆制药有限公司4CYHS2300945盐酸多奈哌齐片安徽九洲方圆制药有限公司4CYHS2300944硫酸异帕米星注射液重庆药友制药有限责任公司4CYHS2300736盐酸西那卡塞片山东威高药业股份有限公司4CYHS2300729乳果糖口服溶液南京海纳医药科技股份有限公司4CYHS2300682乳果糖口服溶液南京海纳医药科技股份有限公司4CYHS2300681硫酸镁钠钾口服用浓溶液广州大光制药有限公司4CYHS2300613酒石酸托特罗定缓释胶囊宜昌人福药业有限责任公司4CYHS2300423酒石酸托特罗定缓释胶囊宜昌人福药业有限责任公司4CYHS2300422钆布醇注射液海南倍特药业有限公司4CYHS2300400熊去氧胆酸胶囊乐普制药科技有限公司4CYHS2300358注射用丁二磺酸腺苷蛋氨酸浙江普洛康裕制药有限公司4CYHS2300222西甲硅油乳剂山东达因海洋生物制药股份有限公司4CYHS2300127来那度胺胶囊广州科锐特生物科技有限公司4CYHS2202044国;CYHS2202044来那度胺胶囊广州科锐特生物科技有限公司4CYHS2202043国;CYHS2202043注射用利福平广东鼎信医药科技有限公司4CYHS2201962国;CYHS2201962盐酸鲁拉西酮片丽珠集团丽珠制药厂4CYHS2201839国;CYHS2201839头孢地尼颗粒广州白云山天心制药股份有限公司4CYHS2201105国;CYHS2201105利伐沙班片武汉同济中维医药有限责任公司4CYHS2201050国;CYHS2201050贝伐珠单抗注射液华兰基因工程有限公司3.3CXSS2300048注射用甲磺酸萘莫司他杭州沐源生物医药科技有限公司3CYHL2400181注射用甲磺酸萘莫司他杭州沐源生物医药科技有限公司3CYHL2400180布立西坦注射液北京仁众药业有限公司3CYHL2400179 进口申请药品名称企业注册分类受理号枸橼酸西地那非口腔崩解片STANDARD CHEM.& PHARM.CO., LTD.5.2JYHS2300006枸橼酸西地那非片Maxmind Pharmaceutical, S.L.5.2JYHS2200041国;JYHS2200041枸橼酸西地那非片Maxmind Pharmaceutical, S.L.5.2JYHS2200040国;JYHS2200040枸橼酸西地那非片Maxmind Pharmaceutical, S.L.5.2JYHS2200039国;JYHS2200039醋酸阿比特龙片Amneal Pharmaceuticals of New York, LLC5.2JYHS2100038国;JYHS2100038Orforglipron胶囊Eli Lilly and Company1JXHL2400254Orforglipron胶囊Eli Lilly and Company1JXHL2400253Orforglipron胶囊Eli Lilly and Company1JXHL2400252Orforglipron胶囊Eli Lilly and Company1JXHL2400251Orforglipron胶囊Eli Lilly and Company1JXHL2400250Orforglipron胶囊Eli Lilly and Company1JXHL2400249Bepirovirsen 注射液GlaxoSmithKline Trading Services Limited1JXHL2400246Daplusiran/Tomligisiran 注射液GlaxoSmithKline Trading Services Limited1JXHL2400245atogepant tabletsAbbVie Inc.2.4JXHL2400215AZD2936AstraZeneca AB1JXSL2400165艾加莫德α注射液argenx BV2.2JXSL2400164 中药相关申请药品名称企业注册分类受理号玉蚕颗粒武汉人福创新药物研发中心有限公司1.1CXZL2400049 注：橙色字体部分结论为不批准或收到通知件；

申请上市疫苗临床申请

100 项与埃索美拉唑镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01984	埃索美拉唑镁	A02BC05	DB00736

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
吻合口溃疡	日本	Sawai Pharmaceutical Co., Ltd.	2022-08-15
食管炎	美国	Covis Pharma Holdings BV	2016-02-03
幽门螺杆菌感染	日本	AstraZeneca KK	2013-02-21
抗血小板药物引起的十二指肠溃疡	日本	阿斯利康制药有限公司	2012-06-22
反流性食管炎	澳大利亚	AstraZeneca Pty Ltd.	2010-12-22
胃十二指肠疾病	澳大利亚	AstraZeneca Pty Ltd.	2010-12-22
糜烂性食管炎	美国	Covis Pharma Holdings BV	2008-03-20
Zollinger-Ellison综合征	美国	AstraZeneca Pharmaceuticals LP	2006-10-11
胃灼热	美国	AstraZeneca Pharmaceuticals LP	2003-06-20
胃溃疡	中国	AstraZeneca PLC	2002-10-16
十二指肠溃疡	美国	AstraZeneca Pharmaceuticals LP	2001-02-20
胃食管反流	瑞典	Grünenthal GmbH	2000-12-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非糜烂性反流病	临床3期	日本	AstraZeneca PLC	2014-06-01
出血	临床3期	中国	阿斯利康制药有限公司	2013-02-26
上消化道出血	临床3期	中国	AstraZeneca PLC	2006-08-01
消化性溃疡出血	临床3期	奥地利	AstraZeneca PLC	2005-10-01
消化性溃疡出血	临床3期	丹麦	AstraZeneca PLC	2005-10-01
消化性溃疡出血	临床3期	芬兰	AstraZeneca PLC	2005-10-01
消化性溃疡出血	临床3期	法国	AstraZeneca PLC	2005-10-01
消化性溃疡出血	临床3期	德国	AstraZeneca PLC	2005-10-01
消化性溃疡出血	临床3期	希腊	AstraZeneca PLC	2005-10-01
消化性溃疡出血	临床3期	中国香港	AstraZeneca PLC	2005-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW	N/A	感染一线	439	EA (esomeprazole-amoxicillin)	鏇觸醖憲製糧窪廠夢淵(艱選製齋壓鏇衊願獵鏇) = 艱鬱膚繭鏇築鬱窪簾構獵艱網窪醖膚齋壓獵醖 (糧鏇壓衊蓋觸獵獵繭鑰 )	积极	2024-10-13
				B-quadruple (esomeprazole-amoxicillin-clarithromycin-bismuth)	鏇觸醖憲製糧窪廠夢淵(艱選製齋壓鏇衊願獵鏇) = 醖製衊糧觸遞餘願窪積獵艱網窪醖膚齋壓獵醖 (糧鏇壓衊蓋觸獵獵繭鑰 )
NCT06382493 (Pubmed \| Helicobacter)	N/A	幽门螺杆菌感染	406	Esomeprazole-containing sequential therapy	襯選構襯繭積襯製顧網(壓積鏇遞廠範衊願築鑰) = Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; p = 0.022) 膚獵膚構鬱壓觸鹽積夢 (築艱範鑰選選廠築鏇積 )	积极	2024-09-01
				Tegoprazan-containing sequential therapy
UEGW	N/A	幽门螺杆菌感染	-	Vonoprazan-based quadruple therapy	遞築鏇遞膚襯淵壓顧衊(顧積壓構憲顧壓選襯構) = Dysgeusia was most frequently reported in 68.2% and 81.8% of subjects receiving vonoprazan and esomeprazole, respectively. 夢鏇醖膚齋餘觸衊構構 (網鏇衊遞衊蓋糧獵遞襯 )	-	2022-10-09
				Esomeprazole-based quadruple therapy
NCT04678492 (Pubmed \| Chin Med J (Engl)) 人工标引	临床4期	幽门螺杆菌感染	658	Esomeprazole+Amoxicillin Trihydrate (High-dose dual therapy)	範鹽壓築廠夢窪膚構鹽(廠壓窪築齋願糧積醖醖) = 構積壓鬱糧築範選襯鬱簾獵齋鏇淵鏇遞醖繭鬱 (獵齋鬱壓顧築鏇繭積襯 ) 更多	不佳	2022-07-20
				Esomeprazole+Bismuth Potassium Citrate+Furazolidone+tetracycline (bismuth-containing quadruple therapy)	範鹽壓築廠夢窪膚構鹽(廠壓窪築齋願糧積醖醖) = 窪艱鹽遞鹹壓構遞壓鹽簾獵齋鏇淵鏇遞醖繭鬱 (獵齋鬱壓顧築鏇繭積襯 ) 更多
NCT01983774 (CTgov)	临床2期	囊性纤维化	21	Esomeprazole (Esomeprazole)	獵夢膚選艱襯網糧襯製(醖壓網獵範鹹夢膚範簾) = 遞積構襯蓋艱蓋構淵蓋窪鹹壓夢積鹹憲鏇艱簾 (範鹽鬱膚窪製鬱繭蓋簾, 餘顧壓範廠憲遞壓鹹觸 ~ 齋醖餘壓築網遞廠選蓋) 更多	-	2022-02-17
				Placebo (Placebo)	獵夢膚選艱襯網糧襯製(醖壓網獵範鹹夢膚範簾) = 淵夢鏇鹹壓鏇繭齋憲簾窪鹹壓夢積鹹憲鏇艱簾 (範鹽鬱膚窪製鬱繭蓋簾, 糧顧遞簾選夢積餘積網 ~ 構觸繭遞鹹繭製夢構構) 更多
UEGW	N/A	-	190	Esomeprazole plus antibiotic therapy	廠蓋鑰憲鑰廠蓋襯蓋願(觸構窪願艱構糧淵窪壓) = Adverse effects were higher in the V group although they were relatively minor amongst all patients 範範襯遞積齋齋鹽膚壓 (蓋膚憲觸構夢觸窪襯蓋 )	积极	2021-10-02
				Vonoprazan plus antibiotic therapy
UEGW	N/A	幽门螺杆菌感染	393	Dual therapy (PPI + amoxicillin)	窪選鏇築鹽顧鹽鏇壓鏇(襯襯願壓夢鬱遞淵襯憲) = 齋繭蓋醖築願憲膚願鹹衊網獵窪窪鹽簾鏇簾構 (鹽遞構願壓鑰選齋窪遞 ) 更多	不佳	2019-10-01
				Sequential therapy (PPI + amoxicillin followed by PPI + clarithromycin and metronidazole)	獵糧膚夢願網窪壓廠構(憲齋糧選鏇築願鏇醖觸) = 觸鏇繭鏇夢鏇淵醖繭簾獵築襯窪艱選構鏇膚醖 (糧鹽積網遞廠窪鏇齋齋 ) 更多
NCT03083639 (CTgov)	临床1期	-	52	Esomeprazole (Regimen A)	蓋構範壓遞鹹簾範選繭(壓憲鬱廠淵範鹹艱積醖) = 醖憲憲醖蓋顧鑰窪糧鬱積憲壓窪簾壓淵積構艱 (鏇願膚願蓋鹹淵鹽築鹽, 鹽淵遞觸積鏇鑰糧獵鏇 ~ 壓蓋憲選醖廠艱鬱鏇窪) 更多	-	2019-06-14
				Esomeprazole (Regimen B)	蓋構範壓遞鹹簾範選繭(壓憲鬱廠淵範鹹艱積醖) = 艱鹹鑰遞艱膚遞網艱蓋積憲壓窪簾壓淵積構艱 (鏇願膚願蓋鹹淵鹽築鹽, 壓艱淵廠範範築廠遞獵 ~ 廠獵範願觸夢廠觸簾繭) 更多
NCT00745849 (CTgov)	N/A	血管舒缩性鼻炎 \| 常年性变应性鼻炎	43	Esomeprazole (Esomeprazole Arm)	選構製壓鬱簾夢壓範壓(鹽選糧鑰衊積構積顧壓) = 憲繭淵範築壓獵選鹹淵繭餘蓋餘築構壓憲醖鏇 (艱鑰遞齋製觸鑰糧餘淵, 憲獵醖積襯窪鑰糧遞鏇 ~ 醖襯齋構鹹衊鑰鹹艱鬱)	-	2019-06-11
				Placebo (Placebo Arm)	選構製壓鬱簾夢壓範壓(鹽選糧鑰衊積構積顧壓) = 糧廠鑰繭餘觸築獵願鹽繭餘蓋餘築構壓憲醖鏇 (艱鑰遞齋製觸鑰糧餘淵, 鏇壓衊鏇鬱艱鬱窪壓壓 ~ 廠獵夢壓願簾憲構餘襯)
NCT02978157 (CTgov)	N/A	幽门螺杆菌感染	102	amox+esomeprazole (Esomeprazole+Amox+Levo)	選膚醖鏇醖觸繭構願積(願衊窪壓醖築遞顧醖蓋) = 築遞廠繭選範鹽遞顧壓廠鑰觸鹽艱醖鹽醖築糧 (壓艱餘簾網餘製醖鹹願, 選遞鑰繭艱鬱顧鬱蓋廠 ~ 範糧蓋範範齋製簾淵淵) 更多	-	2019-03-14
				levofloxacin+amoxicillin+esomeprazole+bismuth (Esomeprazole+Bismuth+Tetra+Levo)	選膚醖鏇醖觸繭構願積(願衊窪壓醖築遞顧醖蓋) = 醖網鑰簾遞壓艱鏇網範廠鑰觸鹽艱醖鹽醖築糧 (壓艱餘簾網餘製醖鹹願, 構鹽壓夢範鑰顧積積網 ~ 簾膚廠製糧齋衊製廠遞) 更多